•    Maxion Therapeutics expands its Cambridge headquarters and doubles the size of its offices and laboratory space
•    Howard Group provides tailored real estate solution to support the biotech’s growth

Cambridge, 20th May 2025: Leading regional property investor and developer Howard Group, is delighted to announce that pioneering biotechnology company Maxion Therapeutics has more than doubled its footprint at Unity Campus.

Following its successful £58 million ($72 million) Series A funding round earlier this year, Maxion has signed a new lease for Suite 5 at The Works building, securing nearly 9,000 sq ft of additional transformative laboratory and office space at Unity Campus to support the next stage of its growth journey.

The new space will enable Maxion, which first moved to Unity Campus in 2023, to continue scaling its research and development activities from a single, cohesive location, as it works towards its ultimate goal of improving the quality of life of patients with debilitating diseases.

Howard Group worked closely with Maxion to create a tailored real estate solution, aligning the new lease for Suite 5 with Maxion’s existing lease on Suite 4 (7,644 sq ft). This synchronisation offers important operational benefits and avoids unnecessary disruption to Maxion’s critical R&D work at Unity Campus.

The expansion takes Maxion’s total space at Unity Campus to over 16,000 sq ft.

Katherine Friend, Director – Investment and Asset Management, Howard Group, said: "It has been a pleasure to see Maxion Therapeutics’ progress since joining Unity Campus, and we are thrilled to support them on their growth journey as they increase their real estate footprint. The ability to provide flexible, high-quality lab and office space solutions that enable our member companies to scale and stay within the Campus, and the wider Cambridge ecosystem, is central to our vision.”

Founded in 2019, Maxion Therapeutics leverages its revolutionary KnotBody® technology to develop antibody-based drugs for previously untreatable ion channel- and G protein-coupled receptor (GPCR)-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease. Its recent landmark fundraising – one of the largest European private biotech financings since the beginning of 2024 – highlights the significant potential of the technology and development pipeline.

Arndt Schottelius, MD PhD, Maxion’s Chief Executive Officer, added: “This new space helps expand our translational biology as well as research and development capabilities and comes at an exciting time for Maxion following our recent Series A fundraising. It will play an important role in progressing our lead KnotBody programme, MAX001, in preclinical development to target a broad spectrum of inflammatory diseases such as atopic dermatitis and inflammatory bowel disease.”

Maxion’s expansion is the latest example of the strong demand for high-quality, flexible laboratory and office space in South Cambridge, as the region’s life sciences industry continues to thrive. With its combination of best-in-class facilities, strong community ethos and focus on wellbeing, Unity Campus is ideally positioned to support the next generation of science and technology businesses as they scale and innovate.

For more information visit www.unitycampus.co.uk.